Treatment of several of these cell lines with the calpain inhibitor calpeptin resulted in podoplanin accumulation, whereas lactacystin, a specific inhibitor of the proteasome, had no effect. In vitro experiments show that podoplanin is a substrate of calpain-1. These results indicate that at least in some tumour cells absence or reduced podoplanin protein levels are due to post-translational calpain-mediated proteolysis. We also report in this article the identification of a novel podoplanin isoform that originates by alternative splicing and differs from the standard form in lacking two cytoplasmic residues (YS). YS dipeptide is highly conserved across species, suggesting that it might be functionally relevant.
Introduction
Podoplanin is a small mucin-like transmembrane protein originally identified as a marker of glomerular epithelial (podocyte) cells (Breiteneder-Geleff et al., 1997; Breiteneder-Geleff et al., 1999) . It was also characterized in distinct biological contexts under a variety of names. For example: as T1 α, a marker for alveolar epithelial cells (Rishi et al., 1995) ; as PA2.26, a cell-surface antigen induced in epidermal keratinocytes during wound healing and chemical carcinogenesis (Gandarillas et al., 1997; Scholl et al., 1999) ; as gp40/gp36, a main receptor for the influenza C virus (Zimmer et al., 1995; Zimmer et al., 1999) ; and as Aggrus, a platelet aggregation-inducing glycoprotein expressed on the surface of tumour cells (Kato et al., 2003) . The interest in this membrane glycoprotein has increased over the years due to several reasons. First, it is a specific marker for the lymphatic endothelium (Breiteneder-Geleff et al., 1999) .
Second, podoplanin null mice die at birth due to malformation of alveoli (Ramirez et al., 2003) . These mice also show defects in the lymphatic vascular system (Schacht et al., 2003) . Third, podoplanin expression is up-regulated in a variety of human cancers, including testicular germ cell tumours (Schacht et al., 2005; Kato et al., 2005) , mesotheliomas (Chu et al., 2005) and different types of carcinomas (Kato et al., 2003; Kato et al., 2005; Martin-Villar et al., 2005; Schacht et al., 2005; Wicki et al., 2006) . Several data indicates that podoplanin plays an important role in malignant progression (reviewed in Wicki and Christofori, 2007) . Kato and co-workers have proposed a prometastatic function for podoplanin based on its ability to induce platelet aggregation associated with the development of arrested tumour emboli (Kato et al., 2004) . Moreover, we have demonstrated that podoplanin can promote an epithelial to mesenchymal transition (EMT) associated with increased cell migration, invasion and metasasis (Martín-Villar et al., 2006; Ramirez et al., 2003; Scholl et al., 2000; Scholl et al., 1999) . This phenotypic conversion depends on the binding of the cytoskeletal-membrane linker ezrin to the cytoplasmic domain of podoplanin, which leads to the activation of RhoA GTPase (Martín-Villar et al., 2006) . Nevertheless, other studies have shown that podoplanin destabilizes cell-to-cell adhesion and promotes cell migration without inducing EMT (Martin-Villar et al., 2005; Wicki et al., 2006) .
Due to its role in tumour progression the regulation of podoplanin expression is of great interest. Several cDNA sequences encoding an identical 162-amino acids human podoplanin polypeptide have been reported by us and others (Ma et al., 1998; Zimmer et al., 1999; Martin-Villar et al., 2005) . Comparison of these sequences with genomic data bases predicts 6 exons and 5 introns within the PDPN gene locus (MartinVillar et al., 2005) . The first exon contains a 5' UTR of about 203 nt before the ATG initiation codon. The last exon contains the termination codon followed by a long UTR of 1 769 nt which includes a 200 nt AluSc sequence in the reverse orientation at the 3' end. The PDPN gene is transcribed into two mRNAs of about 2.7 kb and 0.9 kb in normal human tissues (Kriehuber et al., 2001; Martin-Villar et al., 2005) . While the larger transcript fits the 2 737 nt size reported by us for the PDPN cDNA sequence (Martin-Villar et al., 2005) , the origin of the 0.9 kb was unknown until now.
In this article, we show that podoplanin expression is regulated by a number of mechanisms. First, alternative polyadenylation signals account for the two 2.7 kb and 0.9 kb PDPN transcripts expressed in normal tissues and cell lines. Second, an alternative splicing mechanism gives rise to a PDPN mRNA form encoding a shorter (160-amino acids) protein lacking two residues at the C-terminus. Third, in several human cell lines podoplanin protein expression is downregulated by proteolytic degradation mediated by calpain.
Materials and methods

Cell culture
Cell lines were grown in DMEM supplemented with 10% FBS, 1 unit/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine. The neuroblastoma cell line SHSY5Y and the embryonal carcinoma cell line NCCIT were cultured in RPMI medium with 15% FBS.
MCF10A cells were cultured in DMEM:F12 (1:1), supplemented with 10% goat serum, 10 μg/ml insulin, 20 ng/ml EGF, 0.5 μg/ml hydrocortisone, and 0.1 µg/ml cholera toxin. NIHOVCAR-3 cells were grown in DMEM with 10% FBS. All cells were routinely cultured in 5% CO2 at 37ºC. Pancreatic carcinoma cell lines (IMIM-PC-1, IMIM-PC-2, Panc-1, SKPC-1 and RWP-1), were kindly provided by Dr. F.X. HN30, SCC13 and HT1080 cells were treated with 50µM N-acetyl-Leu-LeuNorleu-al (ALLN) (Calbiochem) and 10µM MG132 (Calbiochem) to inhibit both the proteasome and calpain proteolytic activities. To inhibit specifically either the proteasome or calpain function, cells were treated with 10 µM Lactacystin or 50µM calpeptin (Calbiochem), respectively. The inhibitors were dissolved in dimethylsulfoxide (DMSO) and cells treated with vehicle only were also included as controls. After 14h of incubation, cell lysates were obtained in RIPA buffer (0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 7.5) and a cocktail of protease inhibitors and analysed by Western blotting.
Western blot analysis and antibodies
Cell lysates were obtained in RIPA buffer and analyzed by western blotting after electrophoresis in 10% SDS-PAGE, as described previously (Martin-Villar et al., 2005) . Two different anti-human podoplanin antibodies were used. Ab1 is a polyclonal antibody against a synthetic peptide comprising amino acids 37-5 1 (P 37-51 ) of the human podoplanin ectodomain (Martin-Villar et al., 2005) , and Ab2 is a polyclonal anti-human podoplanin antibody against the entire podoplanin ectodomain purchased from Cell Sciences. Ab1 and Ab2 were used at a dilution of 1:8000 and at 1 µg/ml, respectively.
As a control, Ab1 was preincubated with an excess of either P 37-51 (3 µg/ml) or an unrelated peptide, for 30 min, in order to verify the specificity of recognition (MartinVillar et al., 2005) . Antibodies for α-tubulin (DM1A) and -actin (both from SigmaAldrich) were used at 1:10 000 dilution; antibodies for Smad2/3 (Cell Signaling) and β-catenin (BD Biosciences) were used at 1:1 000 and 1:100, respectively, and antibody for Spectrin (Millipore, MAB1622) was used at 2x10 -2 µg/ml. Horseradish-peroxidaseconjugated sheep anti-mouse (Amersham Biosciences) and goat antirabbit (Biosciences)
IgGs were used as secondary antibodies.
In vitro digestion with calpain-1
NCCIT and MDCK-PDPN-EGFP (Martín-Villar et al., 2006) cells were lysed with RIPA buffer containing 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 10 µg/ml aprotinin and 10 µg/ml pepstatin. Extracts were centrifuged at 14 000 rpm for 15 min.
Reaction mixtures containing 50 mM TrisCl, pH 7.5, 5 mM DTT, 2.5 mM CaCl 2 and 30 µg of protein., were digested with various amounts of calpain-1 (Calbiochem), as shown in Fig. 5C . Digestions were carried out for 30 min at 37ºC and analysed by western blotting.
Northern-blot and RT-PCR analysis
70-80% confluent cells were used to obtain total RNA with the Rneasy (Qiagen)
kits. Twenty µg of total RNA from different cells lines were electrophoresed in 1% agarose gels with 0.41 M formaldehyde and transferred downwards with 10xSSC as described (Chomczynski and Mackey, 1994) . Hybridization was done with 10 6 cpm/ml of 32 P-labeled PDPN cDNA (Martin-Villar et al., 2005) using the conditions of Church and Gilbert .
Reverse transcription was performed at 37°C for 2 hours using the enzyme from avian myeloblastosis virus (Promega), 2µg of total RNA extracted from the cell lines, and random hexadeoxynucleotides as primers. The products of the reaction were used for PCR (30 cycles: 94°C for 1 minute, 59°C for 1 minute 30 seconds, and 72°C for 1 minute 30 seconds) in a Gene Amp PCR system 2400 (Perkin Elmer, Foster City, CA). For human podoplanin amplification the following oligonucleotides were used: 5'-CGGGAACGATGTGGAAGGTGTCA (forward) and 5'-GGGACAGGGCACAGAGTCAGAAAC (reverse). Oligonucleotides for glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) amplification have been described elsewhere (Scholl et al., 2000) .
Determination of the Origin of Transcription
Primer extension was done with oligodeoxynucleotides 5'-GGAAAATTAAAAAGCACCGCGGCCACAG (positions -57 to -84 from the initiation codon) and 5'-GTTGAGTTGTTGCTCTCCTGGGGGCCGAGC (positions -8 to -37 from the initiation codon). Oligodesoxynucleotides (10 pmol) were labelled with 50 Ci [-32 P]ATP using polynucleotide kinase as described by Sambrok and
Russell . The primer extension reaction was carried out with 15 µg of NCCIT total RNA. Annealing, reverse transcription and electrophoresis of the products in 6% acrylamide gels in the presence of 7M urea was essentially done as described (Sambrook and Russell, 2001 ).
3'-RACE
To characterize polyadenylation sites, we used total RNA from NCCIT or universal direct primer using the same amplification protocol. PCR products were ligated to pGEM-Teasy vector (Promega) overnight at 16ºC and plated on 100 µg/ml ampicilin agar plates. Positive colonies were detected by colony PCR with M1 3 direct and reverse universal primers in a 20 µl reaction volume using the above conditions. Ten µl of the reactions were electrophoresed in 1% agarose gels; the remaining volume was diluted five fold with water and 7 µl of the dilution sequenced with the M13-R universal primer in an ABI 377 sequencer.
To study the distal polyadenylation site we carried out the first PCR with oligonucleotide DISTAL-1 -F (5' -GAAACCAAGAGCCAGTTGTCC, positions 1 617-1 637) instead of 6972-F, and the second PCR with DISTAL-3-F (5'-CATATTTGAACACCAGCTGATTGAGAGAAGG, positions 2 459-2 489).
Sucrose gradient fractionation of polysomes
Sucrose gradient fractionation was performed essentially as described by del Prete et al. Fractions were collected from the top, digested with proteinase K and extracted with phenol:chloroform. RNA was recovered by ethanol precipitation and analysed by
Northern blotting as described above.
Confocal immunofluorescence analysis
Immunofluorescence detection of human podoplanin in KLE cells was performed on cells fixed with 3.7% formaldehyde in PBS, permeabilized with 0.05%
Triton X-100. The podoplanin polyclonal antibody Ab1 was used at 1:500 dilution.
Alexa-488-labeled antirabbit (Molecular Probes) IgG was used as secondary antibody. Staining of nuclei was performed in a solution of 4',6-diamino-2-phenilindole (DAPI, 1 µg/ml; SigmaAldrich). Confocal laser scanning microscopy was performed in a Leica TCS-SP2 microscope (Leica Microsystems, Heidelberg GmbH). Images were taken using a 63x oil (NA 1.32) immersion objective and assembled using Leica Confocal Software 2.0.
Results and discussion
Podoplanin expression in human cell lines
The expression of podoplanin was analyzed in a wide panel of human normal and tumour cell lines by RT-PCR and Western immunoblotting ( Fig. 1 and Table 1 ).
While no expression was found in cell lines derived from colorectal (4/4), pancreatic (5/5), breast (5/5) and ovarian (2/2) carcinomas, significant levels of PDPN transcripts were observed in cultured cells derived from sarcomas (2/2), embryonal carcinomas (2/2), squamous cell carcinomas (6/7), prostate carcinoma (1/1) and endometrial tumours (3/7). PDPN mRNA expression was also detected in several nontumour cell lines (Fig. 1A , Table 1 ). In the PDPN-expressing cell lines, Northern blot analysis revealed the presence of two mRNA species of about 2.7 and 0.9 kb (Fig. 1B) , as previously reported for normal tissues (Kriehuber et al., 2001; Martin-Villar et al., 2005) . Interestingly, in many of the cell lines expressing PDPN transcripts, very low levels or a complete absence of protein was found by Western blot analysis ( Fig. 1C and Table 1 ). In fact, only 2 cell lines out of 17 containing transcripts had high levels of podoplanin protein: KLE, NCCIT (derived from a germ cell tumour and an endometrial carcinoma, respectively). For Western blot studies we used two distinct antibodies that specifically recognize the podoplanin ectodomain, as described in Materials and methods. Overall, there was a good correlation between the results obtained with both antibodies, ruling out the possibility that unsuccessful protein detection in cell lines expressing PDPN transcripts was due to the antibody. A broad band of 35-50 kDa was found in the blot of NCCIT cells (Fig. 1C) , likely indicating a highly heterogeneous pattern of protein glycosylation (Marks et al., 1999; MartinVillar et al., 2005) and/or different states of processing (see below). Confocal immunofluorescence analysis showed that podoplanin was concentrated at the cell surface on plasma membrane protrusions (Fig. 1D) , as previously described (Martín-Villar et al., 2006; Martin-Villar et al., 2005; Scholl et al., 1999) .
Transcriptional heterogeneity of podoplanin
Analysis of NCBI PDPN cDNA sequences revealed the presence of several
ESTs compatible with the existence of multiple transcription start sites (MartinVillar et al., 2005) , a fact recently confirmed by others (Hantusch et al., 2007) . We used primer-extension analysis to map the start site(s) for PDPN gene transcription in NCCIT cells ( Fig. 2A) . The major transcription start site (designated +1) was located 94 bp 5' upstream from the ATG start codon. This site differs from that reported by Hantusch and colleagues in MG63 osteosarcoma cells, in which most transcription initiates at a position 107 bp upstream from the site determined by us.
Thus, transcription initiation of PDPN gene can take place over at least a ~100 bp region, a typical situation in TATA-less and CpG-island enriched promoters (Sandelin et al., 2007) . We have cloned 2 070 bp of the 5' flanking region and performed reporter gene assays by introducing targeted deletions in the sequence. Our results
were essentially similar to those reported before (Hantusch et al., 2007) , showing that the 5' flanking region contains motifs that provide basic podoplanin activity and that silencing motifs are located in a 300 bp region located 700 bp upstream the ATG start codon (data not shown).
While the larger PDPN transcript of ~2.7 kb fits the estimated size of the reported full-length podoplanin mRNA (Martin-Villar et al., 2005) , the shorter mRNA species of ~0.9 kb could represent an alternatively polyadenylated form. In order to test this possibility, we performed Northern blot analysis with RNA isolated from the cell lines HEK-293T and NTERA-2 using probes containing either the coding sequence (A), or most of the 3'-UTR (from positions 989 to 2 152, B) (Fig. 2B , upper panel).
While probe A detected both mRNAs, probe B only recognized the larger transcript (Fig. 2B , lower panel), indicating that the 0.9-kb transcript ends before or immediately after position 989. To define the exact sites of polyadenylation of both mRNAs, we conducted 3'-RACE experiments (using 52 clones obtained from lung RNA and 4 clones from NCCIT cells RNA). Fig. 2C shows the sequence around the polyadenylation site for the short (upper sequence) and long (lower sequence) mRNA species. It is noteworthy that the proximal polyadenylation signal is not the canonical one, and has not been described before (Hu et al., 2005) . We have denoted the proximal polyadenylation signal as ATTAYA because we found T in the fifth position in the lung but C in the NCCIT clones.
Polyadenylation of mRNAs requires the binding of at least two trans-acting factors: the Cleavage and Polyadenylation Specificity Factor (CPSF) that binds the Polyadenylation Signal (PAS), and the Cleavage Stimulation Factor (CstF), which interacts with U-and U/Grich elements downstream the polyadenylation site (Chen and Wilusz, 1998) . However, auxiliary upstream elements (AUE) have been described in a variety of systems (Hu et al., 2005) . Using the PolyA_DB2 server (Lee et al., 2007) several putative elements can be detected in both PDPN mRNA termini, either upstream or downstream of the polyadenylation site. It is interesting to note that strong AUEs are found in the small PDPN mRNA. One of them, AUUUGUAAC, is identical to that found in the SV40 late polyadenylation signal (Schek et al., 1992) and is not present in the large PDPN mRNA. Similar sequences have been described in other systems (Hall-Pogar et al., 2005; Natalizio et al., 2002) , located up to 60 nt before the polyadenylation site. The fact that the distal polyadenylation site lacks this efficiency element could be the explanation for the approximate near similar proportion of both mRNAs expressed in tissues and cell lines, as the strength of the distal versus the proximal PAS could be balanced by the presence of strong AUEs upstream the proximal polyadenylation site.
Identification of a novel podoplanin isoform arising by alternative splicing
During the 3'-RACE analysis described above, we observed the presence of an additional transcriptional variant indicative of an alternate spliced podoplanin form (PDPNΔYS). Both podoplanin isoforms share the extracellular and transmembrane domains, but the PDPN-ΔYS form lacks two residues (YS) from the cytoplasmic tail (Fig. 3A) . Although the cDNAs derived from the 3' RACE analysis showed an equal frequency of occurrence for the standard and ΔYS isoforms in our samples (lung and NCCIT cells), human EST databases predict a higher frequency of the standard isoform (Fig. 3B) . This difference could be explained by the limited number of sequences analyzed in this article. Interestingly, the mouse Pdpn gene contains the same donor/acceptor sites in the boundary between exon 5 and intron 5 that would
give rise to a similar variant lacking two residues (FS) of the endodomain. However, such a podoplanin form is not recorded in mouse databases, and we have been unable to detect it by 3' RACE experiments using different mouse tissues (data not shown).
In this regard, it is interesting to note that recent results show a low conservation of alternative spliced forms between humans and mice (Takeda et al., 2008) .The functional relevance of the human podoplanin ΔYS isoform is unknown at present.
The two amino acids YS are highly conserved across species from fishes to primates, with the exception of mice and rats in which phenyalanine substitutes tyrosine ( 
Podoplanin stability is post-translationally regulated by calpain
To ascertain whether the lack of podoplanin protein in cell lines that contained PDPN transcripts was due to a post-translational mechanism, we studied the association of PDPN mRNAs with polysomes, an indication that mRNAs are being translated (Pradet-Balade et al., 2001; Qin et al., 2007) . A representative analysis is shown in Fig. 4 , showing that both PDPN mRNAs are being translated.
The fact that PDPN mRNAs are bound to the polysomal fractions is a strong indication that podoplanin is being translated. We hypothesized then, that podoplanin, once synthesized is being degraded. Since the proteasome is the main pathway for protein degradation in eukaryotic cells, we treated HN30, SCC13 and HT1080 cells with different proteasome inhibitors. To analyze whether podoplanin is indeed a direct substrate of calpain NCCIT and MDCK-PDPN-EGFP extracts were treated with increasing amounts of calpain-1. As shown in Fig. 5C , calpain-1 was able to partially proteolyze podoplanin producing the accumulation of smaller fragments. As a control, spectrin, a well known calpain substrate was found to be proteolyzed in the same assay.
Structural and sequential determinants for substrates of calpain are not well defined, although PEST sequences (sequences rich in Pro, Glu/Asp and Ser/Thr residues, see Rechsteiner and Rogers, 1996) Open circles, 0.9 kb mRNA; filled circles, 2.7 kb mRNA; dashed line, ratio 28S/18S calculated from the methylene blue staining. Reviewer #1:
1) As explained in the text, we used calpains inhibitors because the proteasome inhibitors we used in first place were also inhibitors of calpains, and we wanted to be sure about the proteolytic system involved in podoplanin degradation. Although the reviewer states that podoplanin is not degraded by calpains, our results in Fig.   5C show, on the contrary, that podoplanin is indeed a direct substrate of this family of proteases.
2) Discussion about the up-regulation of podoplanin after treatment with calpains inhibitors. We think that the phenomenon we see is not up-regulation, but stabilization of the protein.
In the last paragraphs of the manuscript we discuss the framework in which podoplanin is proteolyzed by calpain, in a process necessary to build up and dismantle multi-molecular protein complexes needed to fulfil the dynamics of actin assembly and disassembly needed in cell motility.
Reviewer #2 1) We have changed Fig. 1 in a way that, first, uses the same cell lines for Northern and Western blot analysis, including the cell lines requested by the reviewer, and second, we have arranged them in the same order as they appear in Table 1 .
2) We have had great difficulties with the polysomal gradients for HN30 cells.
These cells express very low levels of podoplanin mRNA and even though all the procedures were done in the presence of several RNAse inhibitors, is was difficult to obtain publication-quality gradients. So we decided to do gradients for other podoplanin-expressing cells (NCCIT, HEK293T and HT1080) in addition to HN30.
In all cases we got PDPN mRNAs in the polysome fractions, so weshow here the HEK293T results as an example.
3) The experiment suggested by the reviewer was actually done, However HEK293T cells did not accumulate podoplanin protein when treated with calpeptin (or lactacystin). This result suggest that other mechanisms may be relevant in this cell type.
In connection with points 2 and 3, we are aware (and we mention it at the end of the manuscript) of the different behaviour of distinct cell types in relation with the regulatory processes we are describing, namely differences in amount of mRNA, or protein or response to the treatments. This is an interesting subject, but we think is out of the scope of this manuscript, that addresses more specifically the several levels of regulation of podoplanin expression. 
